Trial Profile

A Multicenter, Open Label, Phase I/II Clinical Study of CM350 in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CM 350 (Primary)
Indications Liver cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors KeyMed Biosciences

Most Recent Events

04 May 2025 Timeframe for all safety endpoints has been changed. Efficacy endpoint 'Phase II:To evaluate the efficacy of CM350 in advanced glypican-3-positive solid tumors' added newly to primary endpoint. Trial amended with indication 'hepatocellular-cancer(HCC)'.
04 May 2025 Planned number of patients changed from 92 to 248.
04 May 2025 Planned End Date changed from 1 Mar 2025 to 1 Apr 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com